Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/- mice

Nature Medicine
D J RileyW H Lee

Abstract

The retinoblastoma gene (RB) is the prototypic tumor suppressor. Studies to date have demonstrated cancer suppression with tumor cells reconstituted with RB ex vivo and implanted into immunodeficient mice, as well as with germline transmission of a human RB transgene into tumor-prone Rb +/- mice. To mimic the therapy of cancer more closely, spontaneous pituitary melanotroph tumors arising in immunocompetent Rb +/- mice were treated with a recombinant adenovirus carrying RB cDNA. Intratumoral RB gene transfer decreased tumor cell proliferation, reestablished innervation by growth-regulatory dopaminergic neurons, inhibited the growth of tumors, and prolonged the life spans of treated animals.

References

Nov 1, 1992·The Journal of Cell Biology·Y GavrieliS A Ben-Sasson
Sep 24, 1992·Nature·T JacksR A Weinberg
Sep 24, 1992·Nature·A R ClarkeH te Riele
Jul 2, 1992·Nature·D P Lane
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·F D HongW H Lee
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·A AlmasanG M Wahl
Jan 1, 1994·Annual Review of Cell Biology·D J RileyW H Lee
Jan 1, 1993·Methods in Enzymology·C Bonnerot, J F Nicolas
Aug 1, 1994·Nature Genetics·B O WilliamsT Jacks
Sep 1, 1993·Genes & Development·Y J BignonW H Lee
May 14, 1993·Science·R C Mulligan
Feb 1, 1964·Endocrinology·G FALCONI, G L ROSSI

❮ Previous
Next ❯

Citations

Jul 1, 1997·Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie·F RibeaudeauJ Mallet
Nov 27, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S M IpH Y Ngan
Dec 19, 1998·Molecular Medicine Today·M J During, L M Ashenden
Aug 26, 2006·Nature Clinical Practice. Endocrinology & Metabolism·Shereen Ezzat, Sylvia L Asa
Nov 5, 2002·Nature Reviews. Cancer·Sylvia L Asa, Shereen Ezzat
Feb 10, 2000·Annals of the New York Academy of Sciences·A Y NikitinW H Lee
Nov 16, 2004·Molecular and Cellular Biology·Chiaki TakahashiMark E Ewen
Apr 30, 2009·Annual Review of Pathology·Sylvia L Asa, Shereen Ezzat
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·A Y NikitinW H Lee
Nov 4, 2000·Expert Opinion on Investigational Drugs·N Gupta
Aug 2, 2006·Journal of Neuroendocrinology·M H QuentienA Enjalbert
Mar 10, 2001·Experimental Cell Research·L Zheng, W H Lee
Sep 8, 2001·The Journal of Urology·K J HarringtonR G Vile
Aug 10, 2000·The American Journal of Pathology·K L Jordan-SciuttoC A Wiley
Oct 19, 2007·Toxicologic Pathology·Andrea Flesken-NikitinAlexander Yu Nikitin
Jun 24, 2004·Toxicologic Pathology·Jerrold M Ward, Deborah E Devor-Henneman
Sep 1, 1999·Gene Therapy·M T O'Leary, H M Charlton
Oct 27, 2001·Clinical Endocrinology·J R Davis, A S McNeilly
Mar 22, 2002·Nature Reviews. Cancer·F McCormick
Dec 9, 2003·The Journal of Clinical Investigation·Shlomo Melmed
Feb 13, 2001·Endocrinology·U Kaiser
Sep 29, 2006·Expert Review of Anticancer Therapy·Adam M SonabendMaciej S Lesniak
Feb 27, 2010·Expert Review of Endocrinology & Metabolism·Silvia S RodriguezGloria M Console
Jul 23, 2019·Endocrinology·Ombeline HoaPatrice Mollard
Dec 21, 2000·Current Oncology Reports·K Bansal, H H Engelhard

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.